Faye Su

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris et al. · Annals of Oncology · 2018 · 868 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin et al. · Breast Cancer Research · 2020 · 156 citations · Full text

Medicine, Oncology, Pharmacology +16

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet et al. · Nature Communications · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +16

Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium

Qiuyin Cai, Jirong Long, Wei Lu et al. · Human Molecular Genetics · 2011 · 99 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

Fabrice André, Faye Su, Nadia Solovieff et al. · Annals of Oncology · 2023 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17